Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 10/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2995286 | 1.00 | GPR183 (0.41) | GPR183KCNH2PDE4APDE4BPDE4C | |
| SCHEMBL3003786 | 0.96 | GPR183 (0.36) | GPR183KCNH2PDE4APDE4BPDE4C | |
| SCHEMBL3003789 | 0.96 | GPR183 (0.36) | GPR183KCNH2PDE4APDE4BPDE4C | |
| SCHEMBL3003966 | 0.86 | CYP17A1 (0.36) | GPR183KCNH2CYP17A1ACACBFAAH | |
| SCHEMBL3003963 | 0.86 | CYP17A1 (0.36) | GPR183KCNH2CYP17A1ACACBFAAH | |
| SCHEMBL3007110 | 0.85 | GPR183 (0.30) | GPR183KCNH2 | |
| SCHEMBL3007112 | 0.85 | GPR183 (0.30) | GPR183KCNH2 | |
| SCHEMBL2988429 | 0.85 | ACACB (0.39) | GPR183KCNH2CYP17A1RECQLSMN1; SMN2 | |
| SCHEMBL2988431 | 0.85 | ACACB (0.39) | GPR183KCNH2CYP17A1RECQLSMN1; SMN2 | |
| SCHEMBL3002878 | 0.84 | RECQL (0.40) | GPR183KCNH2CYP17A1RECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190776-A1 | Thiazoline and Oxazoline Derivatives and Their Methods of Use | ABBOTT LABORATORIES (US) | 2010-07-29 | — | — | US | claimed |
| EP-2038278-A2 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-03-25 | — | — | EP | claimed |
| US-20080070929-A1 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-20 | — | — | US | claimed |
| WO-2008002956-A2 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-01-03 | — | — | WO | claimed |
| US-8470813-B2 | Thiazoline and oxazoline derivatives and their methods of use | ABBVIE INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20100190776-A1 | Thiazoline and Oxazoline Derivatives and Their Methods of Use | ABBOTT LABORATORIES (US) | 2010-07-29 | — | — | US | disclosed |
| US-7683084-B2 | Thiazoline and oxazoline derivatives and their methods of use | ABBOTT LABORATORIES (US) | 2010-03-23 | — | — | US | disclosed |
| EP-2038278-A2 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080070929-A1 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-20 | — | — | US | disclosed |
| WO-2008002956-A2 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190776-A1 | Thiazoline and Oxazoline Derivatives and Their Methods of Use | OXA1L, CYP3A7, ABAT | GPR183 3365/4885KCNH2 2197/4885PDE4A 1241/4885 |
| US-20080070929-A1 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | OXA1L, CYP3A7, ABAT | GPR183 3365/4885KCNH2 2197/4885PDE4A 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.